Cargando…
Rituximab protects against development of atherosclerotic cardiovascular disease after kidney transplantation: a propensity-matched study
Recent studies have implicated B cells in atherosclerosis and have verified the atheroprotective effect of rituximab. Rituximab is widely used for desensitization in ABO-incompatible or crossmatch-positive kidney transplantation (KT). Using a single-center KT database, we performed propensity-matche...
Autores principales: | Kim, Deok Gie, Lee, Juhan, Seo, Won Jun, Lee, Jae Geun, Kim, Beom Seok, Kim, Myoung Soo, Kim, Soon Il, Kim, Yu Seun, Huh, Kyu Ha |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6848081/ https://www.ncbi.nlm.nih.gov/pubmed/31712593 http://dx.doi.org/10.1038/s41598-019-52942-8 |
Ejemplares similares
-
Effects of rituximab dose on hepatitis B reactivation in patients with resolved infection undergoing immunologic incompatible kidney transplantation
por: Lee, Juhan, et al.
Publicado: (2018) -
Early hospital readmissions after ABO- or HLA- incompatible living donor kidney transplantation
por: Lee, Juhan, et al.
Publicado: (2019) -
Transplant outcomes in positive complement-dependent cytotoxicity- versus flow cytometry-crossmatch kidney transplant recipients after successful desensitization: a retrospective study
por: Kim, Deok Gie, et al.
Publicado: (2019) -
The recovery status from delayed graft function can predict long-term outcome after deceased donor kidney transplantation
por: Lee, Juhan, et al.
Publicado: (2017) -
Clinical impact of serum bilirubin levels on kidney transplant outcomes
por: Lee, Juhan, et al.
Publicado: (2021)